Indian Pharmacopoeia Commission
Why in news?
IPC signed three major Memorandums of Understanding (MoUs) in Nagaland on November 27, 2025
Recent MoUs
- IPC signed three major Memorandums of Understanding (MoUs) in Nagaland on November 27, 2025, with the Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA), and Nagaland State Pharmacy Council.
- These agreements aim to promote the use of Indian Pharmacopoeia Reference Substances in drug testing, enhance pharmacovigilance and materiovigilance activities, and advance patient safety across the state.
- Earlier in September 2025, IPC also signed an MoU with the UP Pharmacy Council to promote rational use of medicines through the National Formulary of India.​
About Indian Pharmacopoeia Commission (IPC)
- Indian Pharmacopoeia Commission is an autonomous institution under the Ministry of Health and Family Welfare, Government of India.​
- Established in 2005 and fully operational from January 1, 2009, to set and update standards for drugs manufactured, sold, and consumed in India.​
- Publishes the Indian Pharmacopoeia (IP), the official book of standards for drug identity, purity, and strength, complying with the Drugs and Cosmetics Act, 1940.​
- Regularly updates IP monographs and publishes the National Formulary of India (NFI) to promote rational use of generic medicines.​
- Provides IP Reference Substances (IPRS) as fingerprints for drug identification and purity testing.​
- Oversees programs like Pharmacovigilance Programme of India (PvPI) and Materiovigilance Programme of India (MvPI) for drug safety monitoring.​
- Member of the Pharmacopoeial Discussion Group (PDG) since 2023, aiding global harmonization of pharmaceutical standards.​
- Has a three-tier structure: General Body, Governing Body, Scientific Body, supported by IPC Secretariat and Indian Pharmacopoeia Laboratory (IPL).​
